Several Companies Post Positive Results in Clinical Trials:
Efalizumab (Raptiva) Appears Safe for Up to 3 years of Psoriasis ...DG News - 23 hours ago... Efalizumab (Raptiva) appears to be safe for up to 3 years of continuous weekly therapy for chronic moderate to severe plaque psoriasis, researchers reported ... Low-Dose Regimens of Acitretin (Soriatine) Effective in the ... DG News
Nucryst Pharmaceuticals granted new acne patentDrugResearcher.com, France - 22 hours ago... of Nucryst's silver for the treatment of acne, inflammatory skin conditions such as atopic dermatitis, and hyperproliferative skin disorders such as psoriasis. ...
Celgene's psoriasis therapy beats expectations in phase IIPharmaceutical Business Review - Mar 7, 2006... Corporation has reported better than expected phase II data evaluating CC-10004 as a potential oral therapy for patients with severe plaque-type psoriasis. ...
Centocor's psoriasis drug posts positive phase III dataPharmaceutical Business Review - Mar 7, 2006... that treatment with Centocor's Remicade resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. ...
Advitech Announces the Introduction of Dermylex in Toronto and ...CCNMatthews (press release), Canada - 4 hours ago... Laboratories Limited ("Jamieson") to conduct a special product introduction program for Dermylex, its product for the management of mild to moderate psoriasis. ...
Bexarotene Gel 1% Enhances Efficacy of Phototherapy for Psoriasis ...DG News - Mar 6, 2006... with bexarotene gel 1% appears to enhance the efficacy of narrowband ultraviolet B (UVB) phototherapy with minimal toxicity in patients with plaque psoriasis. ...
